Press release
Globally, More than 100+ Key Companies are working in the Multiple Myeloma Pipeline Landscape
Multiple Myeloma Pipeline
The Multiple Myeloma Pipeline report also provides the inactive products analysis (dormant and terminated) along with the reasons for dormancy and discontinuation, wherever available. This report provides detailed profiles of the pipeline assets and comparative analysis of clinical and non-clinical stage products.
Multiple Myeloma Overview
Multiple myeloma is a clonal plasma cell proliferative disorder characterized by the abnormal increase of monoclonal paraprotein leading to evidence of specific end-organ damage. Unchecked, the excess production of these plasma cells can ultimately lead to specific end-organ damage. Most commonly, this is seen when at least one of the following clinical manifestations are present: hypercalcemia, renal dysfunction, anemia, or bone pain accompanied by lytic lesions.
Download Sample Report- https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Multiple Myeloma Pipeline Analysis
The report provides insights into:
• The report provides detailed insights about companies that are developing therapies in the Multiple myeloma Market.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple myeloma treatment.
• Multiple myeloma key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Multiple myeloma Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple myeloma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Multiple myeloma Emerging Drugs
• Elranatamab: Pfizer
• Felzartamab: Janssen Pharmaceutical
Multiple Myeloma Therapeutics Analysis
There are approx. 100+ key companies which are developing the therapies Multiple myeloma. The companies which have their Multiple myeloma drug candidates in the most advanced stage, i.e phase III include Janssen Pharmaceuticals
Multiple Myeloma Pipeline Phases
DelveInsight's report covers around 130+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Multiple Myeloma Pipeline Molecule Type
Products have been categorized under various Molecule types such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
Multiple Myeloma Pipeline Companies include-
• Janssen/Pharmacyclics
• Novartis
• Incyte Corporation
• Gracell Biotechnology
• SpringWorks Therapeutics
• Sana Biotechnology
• Cytovia Therapeutics
• Pfizer
• MorphoSys
• Biokine Therapeutics
• Arcellx
• Rapa Therapeutics
• iTeos Therapeutics
• Sorrento Therapeutics
• CARsgen
• Ascentage Pharma
• Cartesian Therapeutics
• Bristol-Myers Squibb
• Juno Therapeutics
• Nanjing IASO Biotherapeutics
• Arch Oncology
• Oncoceutics
• TeneoBio
• Nerviano Medical Sciences, and several others
Multiple Myeloma Pipeline Therapies
• Elranatamab
• PHE885
• STI-1492
• IMC 3253, and several others
Request Sample Report- https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Multiple myeloma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Multiple myeloma- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Venetoclax: AbbVie
9. Mid Stage Products (Phase II)
10. PHE885: Novartis
11. Early Stage Products (Phase I/II)
12. ONC 201: Oncoceutics
13. Early Stage Products (Phase I)
14. TNB 383B: TeneoBio
15. Inactive Products
16. Multiple myeloma Key Companies
17. Multiple myeloma Key Products
18. Multiple myeloma- Unmet Needs
19. Multiple myeloma- Market Drivers and Barriers
20. Multiple myeloma- Future Perspectives and Conclusion
21. Multiple myeloma Analyst Views
22. Multiple myeloma Key Companies
23. Appendix
Do you have any query related to the report? If yes, visit here- https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Contact Us
Yash
info@delveinsight.com
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Globally, More than 100+ Key Companies are working in the Multiple Myeloma Pipeline Landscape here
News-ID: 2699846 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Multiple
Mango AI's Multiple Face Swap Video Tool Changes Multiple Faces Instantly
In today's digital world, creating eye-catching and unique content is essential for standing out. The ability to swap multiple faces in a single video opens up creative possibilities, whether for personalized content, comedy or parody videos, or engaging social media posts. Mango AI, developed by Mango Animate, is excited to announce the launch of its advanced multiple face swap video (https://mangoanimate.com/ai/multiple-face-swap-video) tool, which is designed to simplify the creation of…
Multiple Sclerosis Drugs Market
Global Multiple Sclerosis Drugs Market Size research report offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market.
Get a Sample Copy of the Report at - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100386
Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy and neuroaxonal…
Massive Multiple Input Multiple Output (MIMO) Market May Set New Growth Story
A Latest intelligence report published by MR Forecast with title "Global Massive Multiple Input Multiple Output (MIMO) Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Massive Multiple Input Multiple Output (MIMO) market. This report provides a detailed overview of key factors in the Global Massive Multiple Input Multiple Output (MIMO) Market and factors such as driver, restraint, past and current trends,…
Multiple Sclerosis Drugs Market - Progressing Towards a Cure: Advancing Multiple …
Newark, New Castle, USA: The "Multiple Sclerosis Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Multiple Sclerosis Drugs Market: https://www.growthplusreports.com/report/multiple-sclerosis-drugs-market/7983
This latest report researches the industry structure,…
Multiple Sclerosis Drugs Market - Empowering Resilience, Embracing Possibilities …
Newark, New Castle, USA - new report, titled Multiple Sclerosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Multiple Sclerosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Multiple Sclerosis Drugs market. The report offers an overview of…
Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)…
